Trial Profile
Phase II-study Using Ofatumumab and ESHAP Followed by Autologous Trasplant of Hemopoietic Precursors for the Treatment of Classic Hodgkin's Lymphoma on Relapse, Partial Response or Refractory to First Line Treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
- Indications Hodgkin's disease
- Focus Pharmacogenomic; Therapeutic Use
- 23 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2015 Status changed from recruiting to active,no longer recruiting as reported by ClinicalTrials.gov.
- 16 Sep 2010 New trial record